TEXT ONSCREEN:
[PRIORIX logo]
[cartoon images of children]
PRIORIX: A Choice for MMR Vaccination
Please see full Prescribing Information at PRIORIX.com.
TEXT ONSCREEN:
Indication for PRIORIX
PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.
Important Safety Information for PRIORIX
Contraindications for PRIORIX: Do not administer PRIORIX to individuals with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine or after a previous dose of any measles, mumps, and rubella virus-containing vaccine. Do not administer PRIORIX to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. These individuals are at risk of disseminated vaccine virus infection. Do not administer PRIORIX to individuals who are pregnant. Pregnancy should be avoided for 1 month after vaccination.
Please see additional Important Safety Information at the end of this video and at PRIORIX.com. Please see full Prescribing Information at PRIORIX.com.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.
Contraindications for PRIORIX: Do not administer PRIORIX to individuals with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine or after a previous dose of any measles, mumps, and rubella virus-containing vaccine. Do not administer PRIORIX to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. These individuals are at risk of disseminated vaccine virus infection. Do not administer PRIORIX to individuals who are pregnant. Pregnancy should be avoided for 1 month after vaccination.
Please see additional Important Safety Information at the end of this video and at PRIORIX.com.
TEXT ONSCREEN:
Dr. Leonard Friedland
VP, Scientific Affairs & Public Health
GSK Vaccines
Please see full Prescribing Information at PRIORIX.com.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Hi, my name is Len Friedland. And I’m the Vice President for Scientific Affairs & Public Health for GSK Vaccines. I’m a practicing pediatrician, fellowship-trained in pediatric emergency medicine, and a vaccine research specialist.
In this video, I’ll provide an overview of PRIORIX, including considerations that help make PRIORIX an option for the MMR vaccination your patients need.
TEXT ONSCREEN:
Presentation overview
Please see full Prescribing Information at PRIORIX.com.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
We will start by discussing dosing and how PRIORIX aligns with the CDC-recommended routine immunization schedule for measles, mumps, and rubella, followed by a review of immune response and clinical safety data for PRIORIX. Next, we’ll touch on the worldwide MMR experience of GSK and finally, we’ll review how PRIORIX is supplied and ordered.
TEXT ONSCREEN:
DOSING and SCHEDULE FIT
PRIORIX Dosing and Schedule
Aligns with the CDC-recommended routine immunization schedule for MMR vaccine1,2
PRIORIX has the same indication as M-M-R II1,3
CDC=Centers for Disease Control and Prevention; MMR=measles, mumps, and rubella.
Please see full Prescribing Information at PRIORIX.com.
References: 1. Prescribing Information for PRIORIX. 2. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Reviewed October 7, 2025. Accessed December 1, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf 3. Prescribing Information for M-M-R II.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
To begin, we’ll take a look at the dosing and schedule for PRIORIX, which aligns with the CDC-recommended routine immunization schedule for measles, mumps, and rubella vaccine. PRIORIX has the same indication as the M-M-R II vaccine.
TEXT ONSCREEN:
DOSING and SCHEDULE FIT
PRIORIX Dosing and Schedule
PRIORIX is for subcutaneous use only
After reconstitution, a single dose of PRIORIX is approximately 0.5 mL1
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
PRIORIX is for subcutaneous use. After reconstitution, a single dose of PRIORIX is approximately 0.5 mL.
TEXT ONSCREEN:
DOSING and SCHEDULE FIT
[Table]:
PRIORIX Dose 11
Administered at 12 through 15 months of age
PRIORIX Dose 21
Administered at 4 through 6 years of age
If PRIORIX is not administered according to this schedule, and 2 doses of measles, mumps, and rubella virus vaccine are recommended for an individual, there should be a minimum of 4 weeks between the first and second dose.1
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
The first dose of PRIORIX is administered at 12 through 15 months of age, followed by the second dose, which is given at 4 through 6 years of age.
If PRIORIX is not administered according to this schedule, and 2 doses of measles, mumps, and rubella virus vaccine are recommended for an individual, there should be a minimum of 4 weeks between the first and the second dose.
TEXT ONSCREEN:
DOSING and SCHEDULE FIT
CDC Immunization Schedule Notes for MMR (≤18 years)1
Measles, mumps, and rubella vaccination (minimum age: 12 months for routine vaccination)
Routine vaccination
Note: For dose 1 in children age 12-47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.
MMRV=measles, mumps, rubella, and varicella vaccine.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Reviewed October 7, 2025. Accessed December 1, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Here you can see the CDC routine schedule for measles, mumps, and rubella vaccination.
TEXT ONSCREEN:
DOSING and SCHEDULE FIT
CDC Immunization Schedule Notes for MMR (≤18 years)1
Measles, mumps, and rubella vaccination (minimum age: 12 months for routine vaccination)
Catch-up vaccination
Unvaccinated children and adolescents: 2-dose series at least 4 weeks apart
The maximum age for use of MMRV is 12 years
Minimum interval between MMRV doses: 3 months
For full vaccination recommendations, consult the CDC Immunization Schedules, available on the CDC website.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Reviewed October 7, 2025. Accessed December 1, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Notes from the CDC regarding catch-up vaccination are shown here. For full vaccination recommendations, consult the CDC Immunization Schedules, available on the CDC website.
TEXT ONSCREEN:
DOSING and SCHEDULE FIT
PRIORIX Offers a Seamless Scheduling Transition From Your Current MMR Vaccine1,2
PRIORIX may be1:
Administered as a first dose
Administered as a second dose to individuals who have received a first dose of another measles, mumps, and rubella virus-containing vaccine
Please see full Prescribing Information at PRIORIX.com.
References: 1. Prescribing Information for PRIORIX. 2. Prescribing Information for M-M-R II.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
PRIORIX offers a seamless scheduling transition from your current MMR vaccine.
PRIORIX may be administered as a first dose and also administered as a second dose to individuals who have received a first dose of another measles, mumps, and rubella virus-containing vaccine.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Clinical Study Data
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Now let’s explore the clinical trial data that support the immunogenicity of PRIORIX. The effectiveness of PRIORIX is based on a comparison of immune responses relative to M-M-R II.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 1 in Children 12 Through 15 Months of Age (Study 1)
A randomized, observer-blind, controlled study in the United States (including Puerto Rico), Estonia, Finland, Mexico, and Spain
5003 children 12 through 15 months of age
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
We’ll begin by discussing Study 1, which was a randomized, observer-blind, controlled trial conducted in 5 countries, with a study population of 5003 children 12 through 15 months of age.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 1 in Children 12 Through 15 Months of Age (Study 1)
A first dose of PRIORIX (n=3714) or M-M-R II (n=1289) was given concomitantly with HAVRIX and VARIVAX. Children enrolled in the United States also received PREVNAR 13 concomitantly
Antibody responses to measles, mumps, and rubella viruses were measured by ELISAs using sera obtained 42 days following the first dose of either PRIORIX or M-M-R II1
HAVRIX (Hepatitis A Vaccine); VARIVAX (Varicella Virus Vaccine Live); PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
A first dose of PRIORIX or M-M-R II was given concomitantly with HAVRIX and VARIVAX. Children enrolled in the United States also received PREVNAR 13 concomitantly.
Antibody responses to measles, mumps, and rubella viruses were measured by ELISAs using sera obtained 42 days following the first dose of either PRIORIX or M-M-R II.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 1 in Children 12 Through 15 Months of Age (Study 1)
Immune Responses After the First Dose of PRIORIX Compared With M-M-R II in Children 12 Through 15 Months of Age (ATP Population)1
[Bar Graph]:
SRR*† %: 0; 25; 50; 75; 100
PRIORIX (N=3187-3248): Measles: 98
M-M-R II (N=1107-1137): Measles: 98
PRIORIX (N=3187-3248): Mumps: 98
M-M-R II (N=1107-1137): Mumps: 98
PRIORIX (N=3187-3248): Rubella: 97
M-M-R II (N=1107-1137): Rubella: 99
ATP cohort included all vaccinated participants who met protocol-defined criteria for immunogenicity analysis.
ATP=according-to-protocol; CI=confidence interval; N=number of participants; SRR=seroresponse rate.
*Seroresponse rate: the percentage of initially seronegative subjects with concentration above seroresponse threshold for each assay. Seroresponse thresholds are 200 mIU/mL, 10 ELU/mL, and 10 IU/mL for anti-measles, anti-mumps, and anti-rubella antibodies, respectively.
†Noninferiority criterion met for all antigens (lower limit of 2-sided 95% CI for the difference [group receiving PRIORIX minus group receiving M-M-R II] was ≥ -5%).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
This slide shows the seroresponse rates for PRIORIX and M-M-R II after dose 1 in children 12 through 15 months of age.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 1 in Children 12 Through 15 Months of Age (Study 1)
Immune Responses After the First Dose of PRIORIX Compared With M-M-R II in Children 12 Through 15 Months of Age (ATP Population)1
[Bar Graph]:
GMC*: 0; 25; 50; 75; 100 // 3000; 3100; 3200; 3300
PRIORIX (N=3187-3248): Measles (mIU/mL): 3165
M-M-R II (N=1107-1137): Measles (mIU/mL): 3215
PRIORIX (N=3187-3248): Mumps (ELU/mL): 76
M-M-R II (N=1107-1137): Mumps (ELU/mL): 73
PRIORIX (N=3187-3248): Rubella (IU/mL): 53
M-M-R II (N=1107-1137): Rubella (IU/mL): 60
ATP cohort included all vaccinated participants who met protocol-defined criteria for immunogenicity analysis.
ATP=according-to-protocol; CI=confidence interval; ELU/mL=ELISA units per milliliter; GMC=geometric mean antibody concentration adjusted for country; IU/mL=international units per milliliter; mIU/mL=milli-international units per milliliter; N=number of participants.
*Noninferiority criterion met for all antigens (lower limit of 2-sided 95% CI for the ratio [group receiving PRIORIX over group receiving M-M-R II] was ≥0.67).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
On this slide, the geometric mean concentrations (or GMCs) after Dose 1 in children 12 through 15 months of age for PRIORIX and M-M-R II are shown.
TEXT ONSCREEN:
Study 1: Immune responses after the first dose of PRIORIX compared to M-M-R II administered concomitantly with HAVRIX, VARIVAX, and PREVNAR 13 vaccines in children 12 to 15 months of age (ATP)1
[Bar Graph]:
SRR*† %: 0; 25; 50; 75; 100
PRIORIX (N=3187-3248): Measles: 98
M-M-R II (N=1107-1137): Measles: 98
PRIORIX (N=3187-3248): Mumps: 98
M-M-R II (N=1107-1137): Mumps: 98
PRIORIX (N=3187-3248): Rubella: 97
M-M-R II (N=1107-1137): Rubella: 99
[Bar Graph]:
GMC‡: 0; 25; 50; 75; 100 // 3000; 3100; 3200; 3300
PRIORIX (N=3187-3248): Measles (mIU/mL): 3165
M-M-R II (N=1107-1137): Measles (mIU/mL): 3215
PRIORIX (N=3187-3248): Mumps (ELU/mL): 76
M-M-R II (N=1107-1137): Mumps (ELU/mL): 73
PRIORIX (N=3187-3248): Rubella (IU/mL): 53
M-M-R II (N=1107-1137): Rubella (IU/mL): 60
ATP cohort included all vaccinated participants who met protocol-defined criteria for immunogenicity analysis.
PRIORIX or M-M-R II was administered concomitantly with HAVRIX (Hepatitis A Vaccine) and VARIVAX (Varicella Virus Vaccine Live); US participants also received PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine).
ATP=according-to-protocol; CI=confidence interval; ELU/mL=ELISA units per milliliter; GMC=geometric mean antibody concentration adjusted for country; IU/mL=international units per milliliter; mIU/mL=milli-international units per milliliter; N=number of participants; SRR=seroresponse rate.
*Seroresponse rate: the percentage of initially seronegative subjects with concentration above seroresponse threshold for each assay. Seroresponse thresholds are 200 mIU/mL, 10 ELU/mL, and 10 IU/mL for anti-measles, anti-mumps, and anti-rubella antibodies, respectively.
†Noninferiority criterion met for all antigens (lower limit of 2-sided 95% confidence interval (CI) for the difference [group receiving PRIORIX minus group receiving M-M-R II] was ≥-5%).
‡Noninferiority criterion met for all antigens (lower limit of 2-sided 95% CI for the ratio [group receiving PRIORIX over group receiving M-M-R II] was ≥0.67).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
The noninferiority of the immune response after the first dose of PRIORIX compared with M-M-R II was demonstrated in terms of seroresponse rates and antibody geometric mean concentrations to measles, mumps, and rubella viruses.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 2 in Children 12 Through 15 Months of Age (Study 2)
Children 12 through 15 months of age received a first dose of PRIORIX (n=2990) or M-M-R II (n=1526) followed by a second dose of the same vaccine 6 weeks later
A randomized, observer-blind, controlled clinical study in the United States (including Puerto Rico), Czech Republic, Finland, Malaysia, Spain, and Thailand with 4516 participants
In a descriptive analysis of a subset of patients, the immune response after a second dose was similar between the PRIORIX and M-M-R II groups in terms of antibody geometric mean concentrations and seroresponse rates for all antigens1
HAVRIX (Hepatitis A Vaccine); VARIVAX (Varicella Virus Vaccine Live); PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Study 2 was conducted in children 12 through 15 months of age who received a first dose of PRIORIX or M-M-R II followed by a second dose of the same vaccine 6 weeks later. It was a randomized, observer-blind, controlled trial in 6 countries, with 4516 participants.
In a descriptive analysis of a subset of patients, the immune response after a second dose was similar between the group receiving PRIORIX and the group receiving M-M-R II in terms of antibody geometric mean concentrations and seroresponse rates for all antigens.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 2 in Children 4 Through 6 Years of Age (Study 3)
A randomized, observer-blind, controlled study in the United States, South Korea, and Taiwan
4007 children 4 through 6 years of age
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Study 3 was a randomized, observer-blind, controlled study conducted in 3 countries in 4007 children who were 4 through 6 years of age.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 2 in Children 4 Through 6 Years of Age (Study 3)
PRIORIX (n=2917) or M-M-R II (n=1090) was given as a second dose following administration of an initial dose of a combined MMR virus-containing vaccine in the second year of life
PRIORIX and M-M-R II were given concomitantly with KINRIX and VARIVAX in a subset of participants (n=802 receiving PRIORIX, n=298 receiving M-M-R II) enrolled in the United States
Antibody responses to measles, mumps, and rubella viruses were measured by ELISAs using sera obtained 42 days following either PRIORIX or M-M-R II as a second dose1
KINRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine); VARIVAX (Varicella Virus Vaccine Live).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
PRIORIX or M-M-R II was given as a second dose following administration of an initial dose of a combined MMR virus-containing vaccine in the second year of life. In this study, PRIORIX and M-M-R II were given concomitantly with KINRIX and VARIVAX in a subset of participants enrolled in the United States.
Antibody responses to measles, mumps, and rubella viruses were measured by ELISAs using sera obtained 42 days following either PRIORIX or M-M-R II as a second dose.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 2 in Children 4 Through 6 Years of Age (Study 3)
Immune Responses to PRIORIX Compared With M-M-R II as a Second Dose in Children 4 Through 6 Years of Age (ATP Population)1
[Bar Graph]:
SRR*† %: 0; 25; 50; 75; 100
PRIORIX (N=690-698): Measles: 100
M-M-R II (N=245-250): Measles: 100
PRIORIX (N=690-698): Mumps: 100
M-M-R II (N=245-250): Mumps: 100
PRIORIX (N=690-698): Rubella: 100
M-M-R II (N=245-250): Rubella: 100
ATP cohort included all vaccinated participants who met protocol-defined criteria for immunogenicity analysis.
ATP=according-to-protocol; CI=confidence interval; N=number of participants; SRR=seroresponse rate.
*Seroresponse rate: the percentage of participants with concentration above seroresponse threshold for each assay. Seroresponse thresholds are 200 mIU/mL, 10 ELU/mL, and 10 IU/mL for anti-measles, anti-mumps, and anti-rubella antibodies, respectively.
†Noninferiority criterion met for all antigens (lower limit of 2-sided 97.5% CI for the difference [group receiving PRIORIX minus group receiving M-M-R II] was ≥-5%).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Here you see the seroresponse rates for PRIORIX and M-M-R II after dose 2 in children 4 through 6 years of age.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 2 in Children 4 Through 6 Years of Age (Study 3)
Immune Responses to PRIORIX Compared With M-M-R II as a Second Dose in Children 4 Through 6 Years of Age (ATP Population)1
[Bar Graph]:
GMC*: 0; 50; 100; 150; 200 // 4200; 4300; 4400; 4500
PRIORIX (N=690-691): Measles (mIU/mL): 4285
M-M-R II (N=245-248): Measles (mIU/mL): 4333
PRIORIX (N=690-691): Mumps (ELU/mL): 171
M-M-R II (N=245-248): Mumps (ELU/mL): 188
PRIORIX (N=690-691): Rubella (IU/mL): 97
M-M-R II (N=245-248): Rubella (IU/mL): 94
ATP cohort included all vaccinated participants who met protocol-defined criteria for immunogenicity analysis.
ATP=according-to-protocol; CI=confidence interval; ELU/mL=ELISA units per milliliter; GMC=geometric mean antibody concentration adjusted for prevaccination concentration; IU/mL=international units per milliliter; mIU/mL=milli-international units per milliliter; N=number of participants.
*Noninferiority criterion met for all antigens (lower limit of 2-sided 97.5% CI for the ratio [group receiving PRIORIX over group receiving M-M-R II] was ≥0.67).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
And this slide shows the geometric mean concentrations (or GMCs) from the same study.
TEXT ONSCREEN:
Study 3: Immune responses after the second dose of PRIORIX compared to M-M-R II administered concomitantly with KINRIX and VARIVAX in children 4 to 6 years of age (ATP)1
[Bar Graph]:
SRR*† %: 0; 25; 50; 75; 100
PRIORIX (N=690-698): Measles: 100
M-M-R II (N=245-250): Measles: 100
PRIORIX (N=690-698): Mumps: 100
M-M-R II (N=245-250): Mumps: 100
PRIORIX (N=690-698): Rubella: 100
M-M-R II (N=245-250): Rubella: 100
[Bar Graph]:
GMC‡: 0; 50; 100; 150; 200 // 4200; 4300; 4400; 4500
PRIORIX (N=690-691): Measles (mIU/mL): 4285
M-M-R II (N=245-248): Measles (mIU/mL): 4333
PRIORIX (N=690-691): Mumps (ELU/mL): 171
M-M-R II (N=245-248): Mumps (ELU/mL): 188
PRIORIX (N=690-691): Rubella (IU/mL): 97
M-M-R II (N=245-248): Rubella (IU/mL): 94
ATP cohort included all vaccinated participants who met protocol-defined criteria for immunogenicity analysis.
PRIORIX or M-M-R II was administered concomitantly with KINRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) and VARIVAX (Varicella Virus Vaccine Live).
ATP=according-to-protocol; CI=confidence interval; ELU/mL=ELISA units per milliliter; GMC=geometric mean antibody concentration adjusted for prevaccination concentration; U/mL=international units per milliliter; mIU/mL=milli-international units per milliliter; N=number of participants; SRR=seroresponse rate.
*Seroresponse rate: the percentage of participants with concentration above seroresponse threshold for each assay. Seroresponse thresholds are 200 mIU/mL, 10 ELU/mL, and 10 IU/mL for anti-measles, anti-mumps, and anti-rubella antibodies, respectively.
†Noninferiority criterion met for all antigens (lower limit of 2-sided 97.5% CI for the difference [group receiving PRIORIX minus group receiving M-M-R II] was ≥-5%).
‡Noninferiority criterion met for all antigens (lower limit of 2-sided 97.5% CI for the ratio [group receiving PRIORIX over group receiving M-M-R II] was ≥0.67).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND
The noninferiority of PRIORIX to M-M-R II when administered with KINRIX and VARIVAX was demonstrated in terms of antibody seroresponse rates and geometric mean concentrations to MMR viruses at Day 42.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 2 in Participants 7 Years of Age and Older (Study 4)
A randomized, observer-blind, controlled study in the United States, Slovakia, and Estonia
860 participants 7 years of age and older (median age, 26 years; range, 7-59 years)
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Finally, Study 4 was a randomized, observer-blind, controlled study conducted in 3 countries that included 860 participants who were 7 years of age and older.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 2 in Participants 7 Years of Age and Older (Study 4)
PRIORIX (n=426) or M-M-R II (n=434) was given as a second dose following previous administration of a combined MMR virus-containing vaccine
Antibody responses to measles, mumps, and rubella viruses were measured in sera obtained 42 days following the second dose of PRIORIX or M-M-R II1
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Participants received PRIORIX or M-M-R II as a second dose following previous administration of a combined measles, mumps, and rubella virus-containing vaccine.
Antibody responses to measles, mumps, and rubella viruses were measured in sera obtained 42 days following the second dose of PRIORIX or M-M-R II.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 2 in Participants 7 Years of Age and Older (Study 4)
Study 4: Immune Responses to PRIORIX as a Second Dose Compared With M-M-R II in Participants 7 Years of Age and Older (ATP population)1
[Bar Graph]:
SRR*† %: 0; 25; 50; 75; 100
PRIORIX (N=405): Measles: 99
M-M-R II (N=414): Measles: 99
PRIORIX (N=405): Mumps: 98
M-M-R II (N=414): Mumps: 100
PRIORIX (N=405): Rubella: 100
M-M-R II (N=414): Rubella: 100
ATP cohort included all vaccinated participants who met protocol-defined criteria for immunogenicity analysis.
ATP=according-to-protocol; CI=confidence interval; N=number of participants; SRR=seroresponse rate.
*Seroresponse rate: the percentage of participants with concentration above seroresponse threshold for each assay. Seroresponse thresholds are 200 mIU/mL, 10 ELU/mL, and 10 IU/mL for anti-measles, anti-mumps, and anti-rubella antibodies, respectively.
†Noninferiority criterion met for all antigens (lower limit of 2-sided 95% CI for the difference [group receiving PRIORIX minus group receiving M-M-R II] was ≥-5%).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Here, you see the seroresponse rate data for PRIORIX and M-M-R II after dose 2 in participants 7 years of age and older.
TEXT ONSCREEN:
IMMUNE RESPONSE
PRIORIX Immune Response: Dose 2 in Participants 7 Years of Age and Older (Study 4)
Study 4: Immune Responses to PRIORIX as a Second Dose Compared With M-M-R II in Participants 7 Years of Age and Older (ATP population)1
[Bar Graph]:
GMC*: 0; 25; 50; 75; 100; 125 // 1700; 1800; 1900
PRIORIX (N=404): Measles (mIU/mL): 1754
M-M-R II (N=413): Measles (mIU/mL): 1783
PRIORIX (N=404): Mumps (ELU/mL): 114
M-M-R II (N=413): Mumps (ELU/mL): 110
PRIORIX (N=404): Rubella (IU/mL): 76
M-M-R II (N=413): Rubella (IU/mL): 74
ATP cohort included all vaccinated participants who met protocol-defined criteria for immunogenicity analysis.
ATP=according-to-protocol; CI=confidence interval; ELU/mL=ELISA units per milliliter; GMC=geometric mean antibody concentration adjusted for prevaccination concentration; IU/mL=international units per milliliter; mIU/mL=milli-international units per milliliter; N=number of participants.
*Noninferiority criterion met for all antigens (lower limit of 2-sided 95% CI for the ratio [group receiving PRIORIX over group receiving M-M-R II] was ≥0.67).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
And here, you see the geometric mean concentrations (or GMCs) from the same study.
TEXT ONSCREEN:
Study 4: Immune responses to PRIORIX as a second dose compared with M-M-R II in participants 7 years of age and older (ATP population)1
[Bar Graph]:
SRR*† %: 0; 25; 50; 75; 100
PRIORIX (N=405): Measles: 99
M-M-R II (N=414): Measles: 99
PRIORIX (N=405): Mumps: 98
M-M-R II (N=414): Mumps: 100
PRIORIX (N=405): Rubella: 100
M-M-R II (N=414): Rubella: 100
[Bar Graph]:
GMC‡: 0; 25; 50; 75; 100; 125 // 1700; 1800; 1900
PRIORIX (N=404): Measles (mIU/mL): 1754
M-M-R II (N=413): Measles (mIU/mL): 1783
PRIORIX (N=404): Mumps (ELU/mL): 114
M-M-R II (N=413): Mumps (ELU/mL): 110
PRIORIX (N=404): Rubella (IU/mL): 76
M-M-R II (N=413): Rubella (IU/mL): 74
ATP cohort included all vaccinated participants who met protocol-defined criteria for immunogenicity analysis.
ATP=according-to-protocol; CI=confidence interval; ELU/mL=ELISA units per milliliter; GMC=geometric mean antibody concentration adjusted for prevaccination concentration; U/mL=international units per milliliter; mIU/mL=milli-international units per milliliter; N=number of participants; SRR=seroresponse rate.
*Seroresponse rate: the percentage of participants with concentration above seroresponse threshold for each assay. Seroresponse thresholds are 200 mIU/mL, 10 ELU/mL, and 10 IU/mL for anti-measles, anti-mumps, and anti-rubella antibodies, respectively.
†Noninferiority criterion met for all antigens (lower limit of 2-sided 95% CI for the difference [group receiving PRIORIX minus group receiving M-M-R II] was ≥-5%).
‡Noninferiority criterion met for all antigens (lower limit of 2-sided 95% CI for the ratio [group receiving PRIORIX over group receiving M-M-R II] was ≥0.67).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
The noninferiority of the immune response after the second dose of PRIORIX compared with M-M-R II was demonstrated in terms of seroresponse rates and antibody geometric mean concentrations to measles, mumps, and rubella antigens.
TEXT ONSCREEN:
IMMUNE RESPONSE
Coadministration
Study 1: Coadministration with HAVRIX, VARIVAX, and PREVNAR 131
In subsets of children 12 through 15 months of age:
HAVRIX (Hepatitis A Vaccine); VARIVAX (Varicella Virus Vaccine Live); PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Next, we will discuss the immune responses for the vaccines that were coadministered with PRIORIX or M-M-R II.
In Study 1, PRIORIX or M-M-R II was coadministered with HAVRIX, VARIVAX, and PREVNAR 13 in subsets of children 12 through 15 months of age.
TEXT ONSCREEN:
IMMUNE RESPONSE
Coadministration
Study 3: Coadministration with KINRIX and VARIVAX1
In subsets of children 4 through 6 years of age:
KINRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine); VARIVAX (Varicella Virus Vaccine Live).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
In Study 3, PRIORIX or M-M-R II was coadministered with KINRIX and VARIVAX in subsets of children 4 through 6 years of age.
TEXT ONSCREEN:
IMMUNE RESPONSE
Coadministration
In Study 1 and Study 3, there was no evidence that PRIORIX interfered with the antibody responses to the vaccines relative to the antibody responses when M-M-R II was concomitantly administered.
Study 1: coadministered with HAVRIX, VARIVAX, and PREVNAR 13
Study 3: coadministered with KINRIX and VARIVAX1
HAVRIX (Hepatitis A Vaccine); KINRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine); PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine); VARIVAX (Varicella Virus Vaccine Live).
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
In both studies, there was no evidence that PRIORIX interfered with the antibody responses to the vaccines relative to the antibody responses when M-M-R II was concomitantly administered.
TEXT ONSCREEN:
CLINICAL SAFETY
PRIORIX: A Demonstrated Safety Profile
Safety evaluated in 6 clinical trials in which 12,151 participants received at least 1 dose of PRIORIX1
Please see additional Important Safety Information at the end of this video and at PRIORIX.com.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
The safety of PRIORIX was evaluated in 6 clinical trials in which 12,151 participants received at least 1 dose of PRIORIX.
TEXT ONSCREEN:
CLINICAL SAFETY
Most Commonly Reported Solicited Adverse Reactions
The most commonly reported (≥10%) solicited adverse reactions in the following age groups who received PRIORIX in clinical trials were:
12 through 15 months of age (Study 1)—local: pain (26%) and redness (25%); systemic: irritability (63%), loss of appetite (45%), drowsiness (45%), and fever (35%)
4 through 6 years of age—local: pain (41%), redness (22%), and swelling (11%); systemic: drowsiness (27%), fever (24%), and loss of appetite (21%)
7 years of age and older—local: pain (12%) and redness (12%)1
Please see additional Important Safety Information at the end of this video and at PRIORIX.com.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Here are the solicited local and systemic adverse reactions reported in 10% or more of study participants after dose 1 (at 12 through 15 months of age) and dose 2 (at 4 through 6 years of age and 7 years of age and older).
TEXT ONSCREEN:
CLINICAL SAFETY
Safety Evaluation: Dose 1 in Children 12 Through 15 Months of Age (Study 1)
A randomized, observer-blind, controlled study conducted in 5 countries in 5003 children 12 through 15 months of age
A first dose of PRIORIX or M-M-R II was given concomitantly with HAVRIX and VARIVAX. Children enrolled in the United States also received PREVNAR 13 concomitantly1
HAVRIX (Hepatitis A Vaccine); PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine); VARIVAX (Varicella Virus Vaccine Live).
Please see additional Important Safety Information at the end of this video and at PRIORIX.com.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
As described previously, Study 1 was a randomized, observer-blind, controlled trial conducted in children 12 through 15 months of age. Participants were given a first dose of PRIORIX or M-M-R II concomitantly with HAVRIX and VARIVAX. Children enrolled in the United States also received PREVNAR 13 concomitantly.
TEXT ONSCREEN:
Study 1: Incidence of solicited local and systemic adverse reactions after the first dose of PRIORIX compared with M-M-R II in children 12 through 15 months of age (total vaccinated cohort)1,*
[TABLE]:
Adverse Reaction: PRIORIX % (n); M-M-R II % (n)
Local: (within 4 Days†): N=3555; N=1242
Pain: 25.9% (919); 28.1% (349)
Redness: 24.5% (870); 25.2% (313)
Swelling: 8.9% (318); 10.7% (133)
Systemic (within 15 Days†): N=3566; N=1243
Irritability: 63.3% (2258); 65.9% (819)
Loss of appetite: 45.1% (1608); 44.1% (548)
Drowsiness: 44.9% (1601); 47.1% (586)
Systemic (within 43 Days†): N=3566; N=1243
Fever (defined as temperature ≥38°C/100.4°F): 34.9% (1244); 33.1% (412)
Measles/rubella-like rash: 6.6% (235); 6.2% (77)
Febrile convulsions: 0.2% (7); 0.2% (3)
Signs of meningeal irritation‡: 0.1% (3); 0
Parotid/salivary gland swelling: 0; 0
Total vaccinated cohort for safety included all vaccinated participants for whom safety data were available.
N=number of participants; n=number of participants presenting with solicited adverse reaction described.
*HAVRIX (Hepatitis A Vaccine and VARIVAX (Varicella Virus Vaccine Live) were administered concomitantly with PRIORIX or M-M-R II; participants in the United States also received PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine) concomitantly with PRIORIX (n=1847) or M-M-R II (n=654).
†4 Days, 15 Days, and 43 Days included the day of vaccination and the subsequent 3, 14, and 42 days, respectively.
‡Neck stiffness with or without photophobia or headache.
Please see additional Important Safety Information at the end of this video and at PRIORIX.com.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
The most common adverse reactions in Study 1—reported in 10% or more participants 12 through 15 months of age—were pain, redness, irritability, loss of appetite, drowsiness, and fever.
TEXT ONSCREEN:
CLINICAL SAFETY
Safety Evaluation: Dose 2 in Children 12 Through 15 Months of Age (Study 2)
Children 12 through 15 months of age received a first dose of PRIORIX (n=2990) or M-M-R II (n=1526) followed by a second dose of the same vaccine 6 weeks later
The safety profile of PRIORIX following the second dose was similar to the safety profile following the first dose of PRIORIX1
Please see additional Important Safety Information at the end of this video and at PRIORIX.com.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
As described previously, Study 2 was a randomized, observer-blind, controlled clinical trial that included children 12 through 15 months of age who received a first dose of PRIORIX or M-M-R II followed by a second dose of the same vaccine 6 weeks later.
The safety profile of PRIORIX following the second dose was similar to the safety profile following the first dose.
TEXT ONSCREEN:
CLINICAL SAFETY
Safety Evaluation: Dose 2 in Children 4 Through 6 Years of Age (Study 3)
A randomized, observer-blind, controlled study conducted in 3 countries in 4007 children 4 through 6 years of age
PRIORIX or M-M-R II was given as a second dose after administration of an initial dose of a combined MMR virus-containing vaccine in the second year of life
PRIORIX and M-M-R II were given concomitantly with KINRIX and VARIVAX in a subset of participants enrolled in the United States (n=802 receiving PRIORIX, n=298 receiving M-M-R II)1
KINRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine); VARIVAX (Varicella Virus Vaccine Live).
Please see additional Important Safety Information at the end of this video and at PRIORIX.com.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
As discussed previously, Study 3 was a randomized, observer-blind, controlled study that included children 4 through 6 years of age. Participants were given PRIORIX or M-M-R II as a second dose after administration of an initial dose of a combined measles, mumps, and rubella virus-containing vaccine in the second year of life. In a subset of participants, PRIORIX and M-M-R II were given concomitantly with KINRIX and VARIVAX.
TEXT ONSCREEN:
Study 3: Incidence of solicited local and systemic adverse reactions after the second dose of PRIORIX compared with M-M-R II in children 4 through 6 years of age (total vaccinated cohort)1,*
[TABLE]:
Adverse Reaction: PRIORIX % (n); M-M-R II % (n)
Local: (within 4 Days†): N=727; N=267
Pain: 40.6% (295); 40.8% (109)
Redness: 21.6% (157); 25.8% (69)
Swelling: 11.3% (82); 10.5% (28)
Systemic (within 4 Days†): N=731; N=268
Drowsiness: 27.2% (199); 26.9% (72)
Loss of appetite: 21.1% (154); 22.0% (59)
Systemic (within 43 Days†): N=731; N=268
Fever (defined as temperature ≥38°C/100.4°F): 24.2% (177); 25.0% (67)
Measles/rubella-like rash: 1.9% (14); 1.9% (5)
Parotid/salivary gland swelling: 0; 0
Febrile convulsions: 0; 0
Signs of meningeal irritation‡: 0; 0.7% (2)
Total vaccinated cohort for safety included all vaccinated participants for whom safety data were available.
N=number of participants; n=number of participants presenting with solicited adverse reaction described.
*KINRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) and VARIVAX (Varicella Virus Vaccine Live) were administered concomitantly with PRIORIX or M-M-R II.
†4 Days and 43 Days included the day of vaccination and the subsequent 3 and 42 days, respectively.
‡Neck stiffness with or without photophobia or headache.
Please see additional Important Safety Information at the end of this video and at PRIORIX.com.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
In Study 3, the most common adverse reactions reported in 10% or more of a subset of children who received coadministered vaccines—were pain, redness, swelling, drowsiness, loss of appetite, and fever.
TEXT ONSCREEN:
CLINICAL SAFETY
Safety Evaluation: Dose 2 in Participants 7 Years of Age and Older (Study 4)
A randomized, observer-blind, controlled study conducted in 3 countries in 860 participants 7 years of age and older
PRIORIX or M-M-R II was administered as a second dose following an initial dose of an MMR virus-containing vaccine1
Please see additional Important Safety Information at the end of this video and at PRIORIX.com.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
As described previously, Study 4 was a randomized, observer-blind, controlled trial conducted in participants 7 years of age and older who received PRIORIX or M-M-R II as a second dose following previous administration of a combined measles, mumps, and rubella virus-containing vaccine.
TEXT ONSCREEN:
Study 4: Incidence of solicited local and systemic adverse reactions after PRIORIX as a second dose compared with M-M-R II in participants 7 years of age and older (total vaccinated cohort)1,*
[TABLE]:
Adverse Reaction: PRIORIX % (n); M-M-R II % (n)
Local: (within 4 Days†): N=405; N=422
Pain: 12.1% (49); 11.1% (47)
Redness: 11.9% (48); 11.8% (50)
Swelling: 5.7% (23); 6.9% (29)
Systemic (within 43 Days†): N=405; N=422
Fever (defined as temperature ≥38°C/100.4°F): 2.7% (11); 5.5% (23)
Joint Pain (arthralgia/arthritis): 2.0% (8); 0.9% (4)
Parotid/salivary gland swelling: 0.2% (1); 0
Signs of meningeal irritation‡: 0.2% (1); 0.2% (1)
Measles/rubella-like rash: 0; 0.5% (2)
Total vaccinated cohort for safety included all vaccinated participants for whom safety data were available.
N=number of participants; n=number of participants presenting with solicited adverse reaction described.
*Participants received a first dose of either M-M-R II, PRIORIX, or a non-US combined measles, mumps, rubella, and varicella virus vaccine.
†4 Days and 43 Days included the day of vaccination and the subsequent 3 and 42 days, respectively.
‡Neck stiffness with or without photophobia or headache.
Please see additional Important Safety Information at the end of this video and at PRIORIX.com.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
In participants 7 years of age and older, pain and redness were the most common adverse reactions, reported in 10% or more individuals.
For more information on the safety of PRIORIX, please see the end of this video and PRIORIX.com.
TEXT ONSCREEN:
WORLDWIDE EXPERIENCE
GSK Worldwide MMR Vaccine Experience
MMR vaccine from GSK, licensed as PRIORIX (Measles, Mumps, and Rubella Vaccine, Live),* is available in more than 100 countries, including the United States, all European countries, Canada, Australia, and New Zealand1,2
More than 850 million doses of PRIORIX* have been distributed worldwide since 19971
*PRIORIX licensed in the United States contains a higher content of each antigen than PRIORIX licensed in the rest of the world.
Please see full Prescribing Information at PRIORIX.com.
References: 1. Prescribing Information for PRIORIX. 2. Data on file, GSK.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
The MMR vaccine from GSK, licensed as PRIORIX, is available in more than 100 countries, with more than 850 million doses distributed worldwide since 1997.
Note that PRIORIX licensed in the United States contains a higher content of each antigen than PRIORIX licensed in the rest of the world.
TEXT ONSCREEN:
HOW SUPPLIED
How PRIORIX Is Supplied
PRIORIX is supplied as 2 different components in a box1
[image of PRIORIX box]
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Next, we will look at how PRIORIX is supplied. PRIORIX is packaged as 2 components in a box.
TEXT ONSCREEN:
HOW SUPPLIED
How PRIORIX Is Supplied
PRIORIX is supplied as 2 different components in a box1
10 single-dose vials of Lyophilized Antigen Component, Live
10 single-dose prefilled ungraduated syringes of Sterile Water Diluent Component (packaged without needles)
After reconstitution, each vial contains one dose (approximately 0.5 mL) of PRIORIX.1
[Images of PRIORIX box, vial, syringe, PI, and open box with syringe and vial]
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Inside the box are 10 single-dose vials of Lyophilized Antigen Component, Live and 10 single-dose prefilled ungraduated syringes of Sterile Water Diluent Component, packaged without needles. After reconstitution, each vial contains one dose (approximately 0.5 mL) of PRIORIX.
TEXT ONSCREEN:
SUMMARY
Why Choose PRIORIX?
PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older1
PRIORIX has an MMR immunization schedule you know. The dosing schedule for PRIORIX aligns with the CDC-recommended routine immunization schedule for MMR1,2
Please see full Prescribing Information at PRIORIX.com.
References: 1. Prescribing Information for PRIORIX. 2. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Reviewed October 7, 2025. Accessed December 1, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Now, let’s quickly recap what we’ve discussed.
PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.
PRIORIX has an MMR immunization schedule you know. The dosing schedule for PRIORIX aligns with the CDC-recommended routine immunization schedule for MMR.
TEXT ONSCREEN:
SUMMARY
Why Choose PRIORIX?
Please see full Prescribing Information at PRIORIX.com.
References: 1. Prescribing Information for PRIORIX. 2. Prescribing Information for M-M-R II.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
PRIORIX offers a seamless scheduling transition from your current MMR vaccine.
TEXT ONSCREEN:
SUMMARY
Why Choose PRIORIX?
PRIORIX may be1:
[Image of PRIORIX box]
Please see full Prescribing Information at PRIORIX.com.
References: 1. Prescribing Information for PRIORIX. 2. Prescribing Information for M-M-R II.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
PRIORIX may be administered as a first dose, and also administered as a second dose to individuals who received a first dose of another MMR virus-containing vaccine.
TEXT ONSCREEN:
SUMMARY
Why Choose PRIORIX?
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Data on file, GSK
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
The effectiveness of PRIORIX is based on a comparison of immune responses relative to M-M-R II. The safety profile is based on data from 6 clinical trials.
TEXT ONSCREEN:
SUMMARY
Why Choose PRIORIX?
GSK has MMR vaccine experience worldwide. Licensed as PRIORIX (Measles, Mumps, and Rubella Vaccine, Live),* it is available in more than 100 countries, with more than 850 million doses distributed since 19971
*PRIORIX licensed in the United States contains a higher content of each antigen than PRIORIX licensed in the rest of the world.
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Data on file, GSK
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
GSK has MMR vaccine experience worldwide. Licensed as PRIORIX (Measles, Mumps, and Rubella Vaccine, Live), it is available in more than 100 countries, with more than 850 million doses distributed worldwide since 1997.
Note that PRIORIX licensed in the United States contains a higher content of each antigen than PRIORIX licensed in the rest of the world.
TEXT ONSCREEN:
SUMMARY
Why Choose PRIORIX?
[Image of PRIORIX syringe]
Please see full Prescribing Information at PRIORIX.com.
Reference: 1. Prescribing Information for PRIORIX.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Finally, PRIORIX is an MMR vaccine with a syringe prefilled with Sterile Water Diluent Component.
TEXT ONSCREEN:
ORDERING
Order PRIORIX Today:
Call 1-866-475-8222
Visit GSKDirect.com or contact your GSK Sales Representative
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
After watching this video, I hope you have a better understanding of the dosing and scheduling considerations that help make PRIORIX an option for MMR vaccination, as well as the clinical data that support that choice.
You can order PRIORIX today by calling 1-866-475-8222, by visiting GSKDirect.com, or by contacting your GSK Sales Representative.
Now let’s take a look at the additional Important Safety Information for PRIORIX.
TEXT ONSCREEN:
ADDITIONAL IMPORTANT SAFETY INFORMATION
Additional Important Safety Information for PRIORIX
Appropriate medical treatment used to manage immediate allergic reactions must be available in the event an acute anaphylactic reaction occurs following administration of PRIORIX
There is a risk of febrile seizures following immunization with PRIORIX
Thrombocytopenia and thrombocytopenic purpura have been reported following vaccination with PRIORIX
Syncope (fainting) can occur in association with administration of injectable vaccines, including PRIORIX. Procedures should be in place to avoid injury from fainting
The tip caps of the prefilled syringes of diluent contain natural rubber latex, which may cause allergic reactions
Please see additional Important Safety Information at the end of this video and at PRIORIX.com. Please see full Prescribing Information at PRIORIX.com.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Appropriate medical treatment used to manage immediate allergic reactions must be available in the event an acute anaphylactic reaction occurs following administration of PRIORIX.
There is a risk of febrile seizures following immunization with PRIORIX.
Thrombocytopenia and thrombocytopenic purpura have been reported following vaccination with PRIORIX.
Syncope (fainting) can occur in association with administration of injectable vaccines, including PRIORIX. Procedures should be in place to avoid injury from fainting.
The tip caps of the prefilled syringes of diluent contain natural rubber latex, which may cause allergic reactions.
TEXT ONSCREEN:
ADDITIONAL IMPORTANT SAFETY INFORMATION
Additional Important Safety Information for PRIORIX
Vaccination with PRIORIX may not result in protection in all vaccine recipients
In clinical trials, the most commonly reported (≥10%) solicited adverse reactions were:
– Age 12 through 15 months–local: pain (26%) and redness (25%); systemic: irritability (63%), loss of appetite (45%), drowsiness (45%), and fever (35%)
– Age 4 through 6 years–local: pain (41%), redness (22%) and swelling (11%); systemic: loss of appetite (21%), drowsiness (27%), and fever (24%)
– Age 7 years and older–local: pain (12%) and redness (12%)
Please see additional Important Safety Information at the end of this video and at PRIORIX.com. Please see full Prescribing Information at PRIORIX.com.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Vaccination with PRIORIX may not result in protection in all vaccine recipients.
In clinical trials, the most commonly reported (≥10%) solicited adverse reactions were:
Age 12 through 15 months–local: pain (26%) and redness (25%); systemic: irritability (63%), loss of appetite (45%), drowsiness (45%), and fever (35%).
Age 4 through 6 years–local: pain (41%), redness (22%) and swelling (11%); systemic: loss of appetite (21%), drowsiness (27%), and fever (24%).
Age 7 years and older–local: pain (12%) and redness (12%).
TEXT ONSCREEN:
ADDITIONAL IMPORTANT SAFETY INFORMATION
Additional Important Safety Information for PRIORIX
Administration of immune globulins and other blood products concurrently with PRIORIX may interfere with the expected immune response to the vaccine
If a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or at least 4 weeks after PRIORIX to avoid false-negative results
Please see additional Important Safety Information at the end of this video and at PRIORIX.com. Please see full Prescribing Information at PRIORIX.com.
[PRIORIX-GSK logo]
AUDIO - DR. LEN FRIEDLAND:
Administration of immune globulins and other blood products concurrently with PRIORIX may interfere with the expected immune response to the vaccine
If a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or at least 4 weeks after PRIORIX to avoid false-negative results.
TEXT ONSCREEN:
For US healthcare professionals only.
Trademarks are property of their respective owners.
©2025 GSK or licensor.
PMUS-PRIVID250001 December 2025
Produced in USA.
Please see full Prescribing Information at PRIORIX.com.
[PRIORIX-GSK logo]
